NEWS Feed

Latest Articles in this Channel:

01/27/12--07:44: Illumina launches "poison pill" against Roche's takeover bid | MassDevice.com On Call (chan 1636293)

Illumina rebuffs Roche's hostile takeover bid by launching a "poison pill" strategy that allows other existing shareholders to buy additional shares at a discounted price.



MASSDEVICE ON CALL —Illumina's (NSDQ:ILMN) board of directors adopted a "poison pill"strategy in response to a hostile takeover bid by Roche (PINK:RHHBY).

Illumina adopted a rights agreement which allows shareholders other than the a bidder to buy additional shares at a discounted price, potentially deterring would-be bidders by increasing costs.

News Well, Capitol Hill, Cardiovascular, Medicare, Mergers & Acquisitions, Wall Street Beat

read more




01/27/12--09:43: 3M touts record sales and earnings per share for 2011 | Earnings Roundup (chan 1636293)

3M's 4th-quarter profits beat The Street as it affirms its 2012 guidance, but shares stay flat; also, Hill-Rom's Q1 earnings slide 7%; Getinge sees 2011 profits rise 11% despite sales slide; ResMed's Q2 sales, earnings rise; Uroplasty pares Q3 losses on doubled sales; Encision swings to Q3 losses; and EnteroMedics' Q4, 2011 losses rise.



3M Co. (NYSE:MMM) beat expectations for its 4th-quarter profits and affirmed its guidance for 2012, but Wall Street remained unmoved, with shares staying flat in this morning's trading.

News Well, MassDevice Earnings Roundup, Q4, Wall Street Beat

read more




01/27/12--10:15: Cook's chairman on the med-tech tax: We can survive anything (chan 1636293)

Although the impending medical device tax poses a burden to the med-tech industry, the biggest losers are likely to be patients and U.S. workers, Cook Group chairman Stephen Ferguson tells MassDevice.



As House Republicans push forward with a measure to repeal the impending 2.3% medical device levy, Cook Group chairman Stephen Ferguson warns that U.S. patients and workers have the most to lose should the tax be allowed to take effect in 2013.

"You know, Cook can survive anything," Ferguson told MassDevice. "We can deal with these issues, but the people who are manufacturing the devices and the patients who are looking at access to the latest technology, I think, are the 2 groups who will be the most impacted by this."

News Well, Medical Device Tax

read more




01/27/12--12:11: Venture capital outlook a mixed bag | Wall Street Beat (chan 1636293)



The volatility of the stock markets last year was mirrored in the venture capital arena, according to Mark Heesen, president of the National Venture Capital Assn.

"Be prepared for a roller coaster ride here, because that’s where we’ve been for the past year – and that’s where we’re going," Heesen told Xconomy.

News Well, Cardiac Rhythm Management, Replacement Heart Valves, Venture Capital/Private Equity, Wall Street Beat

read more




01/27/12--13:40: Simbionix buys GMV's Arthro VR training simulator | Deals Roundup (chan 1636293)

Simbionix acquires the Arthro VR arthroscopic training simulator from Spain's GMV; also, GPOs Premier, Novation ink new deals; Medquist rebrands as M*Modal; Essilor inks China, Europe deals, adding nearly $45M to its top line; and PPD, VirtualScopics expand alliance.



Simbionix USA Corp. acquired the Arthro VR arthroscopic training simulator line from Spain's GMV for an undisclosed amount.

The deal broadens Simbionix's footprint in the orthopedic training arena. The Arthro VR features a line of simulated procedures using fiberglass limb replicas, 3D images and haptic sensation.

News Well, Deals Roundup, Group Purchasing Organizations

read more




01/27/12--14:33: Cordis sues U.S. Patent Office in latest Stent War scrimmage | Legal News (chan 1636293)

Johnson & Johnson subsidiary Cordis Corp. sued the U.S. Patent & Trademark Office for blocking subpoenas the device maker says led to a win for stent rivals Boston Scientific and Abbott Labs; also, YY; YY; and YY.



Johnson & Johnson (NYSE:JNJ) subsidiary Cordis Corp. sued the U.S. Patent & Trademark Office this week, alleging that the agency denied key subpoenas that prevented it from defending its patents in a stent lawsuit against Boston Scientific (NYSE:BSX) and Abbott Laboratories (NYSE:ABT).

News Well, Insurance, Legal Roundup, Oncology, Patent Infringement, Respiratory, Stent Wars

read more